"The pan-Canadian Oncology Drug Review Expert Review Committee recommends that retifanlimab be reimbursed in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent SCAC only if the conditions listed in ...are met." (Ottawa (ON): Canadian Agency for Drugs and Technologies in Health) Sep 5, 2026
Reimbursement • Anal Squamous Cell Carcinoma • Oncology
|